Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | GABRE | P78334 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1692318 | 1.00 | ROCK2 (0.43) | ROCK2ROCK1LMNAPLGPLAT | |
| SCHEMBL10270877 | 1.00 | ROCK2 (0.43) | ROCK2ROCK1LMNAPLGPLAT | |
| SCHEMBL28283154 | 0.98 | ROCK2 (0.42) | ROCK2ROCK1LMNAPLGPLAT | |
| Hydrochloric Acid SCHEMBL1692312 | 0.98 | ROCK2 (0.42) | ROCK2ROCK1LMNAPLGPLAT | |
| Hydrochloric Acid SCHEMBL1692314 | 0.98 | ROCK2 (0.42) | ROCK2ROCK1LMNAPLGPLAT | |
| SCHEMBL28284574 | 0.95 | ROCK2 (0.41) | ROCK2ROCK1LMNAPLGPLAT | |
| SCHEMBL6274750 | 0.89 | LMNA (0.41) | ROCK2ROCK1LMNAPLGPLAT | |
| SCHEMBL824158 | 0.86 | ACE (0.39) | ROCK2ROCK1LMNAPLGPLAT | |
| SCHEMBL25544633 | 0.86 | ACE (0.39) | ROCK2ROCK1LMNAPLGPLAT | |
| SCHEMBL14436548 | 0.86 | ACE (0.39) | ROCK2ROCK1LMNAPLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059842-A | Synthesis method for improving purity of nateglinide | 天方药业有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| CN-110423509-A | A kind of cigarette tipping paper antibacterial ink and preparation method thereof | ZHEJIANG RONGFENG PAPER CO LTD | 2019-11-08 | — | — | CN | claimed |
| CN-109651129-A | A kind of 4- isopropyl cyclohexanecarboxylic acid turns structure and separation method along anti-mixture | 浙江清和新材料科技有限公司 | 2019-04-19 | — | — | CN | claimed |
| CN-104402756-B | A kind of preparation method of high-purity Nateglinide | 天方药业有限公司 | 2016-08-31 | — | — | CN | claimed |
| US-9150499-B2 | Process for the preparation of nateglinide | CIPLA LIMITED (IN) | 2015-10-06 | — | — | US | claimed |
| US-8658821-B2 | Process for the preparation of nateglinide | CIPLA LIMITED (IN) | 2014-02-25 | — | — | US | claimed |
| EP-1765769-B1 | PROCESS FOR THE PREPARATION OF NATEGLINIDE | CIPLA LTD (IN) | 2013-11-06 | — | — | EP | claimed |
| US-20130165686-A1 | Process for the Preparation of Nateglinide | CIPLA LIMITED (IN) | 2013-06-27 | — | — | US | claimed |
| CN-103159640-A | Preparation method of nateglinide raw material | JIANGSU WANBANG BIOPHARMACEUTICALS CO LTD | 2013-06-19 | — | — | CN | claimed |
| EP-1535900-A1 | Process for the preparation of nateglinide, preferably in b-form | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A. (IT) | 2005-06-01 | — | — | EP | claimed |
| US-6861553-B2 | Process for preparing nateglinide and intermediates thereof | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2005-03-01 | — | — | US | claimed |
| EP-1487782-A1 | PROCESS FOR PREPARING NATEGLINIDE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-12-22 | — | — | EP | claimed |
| US-20040152782-A1 | Process for preparing nateglinide and intermediates thereof | TEVA PHARMACEUTICALS USA, INC. | 2004-08-05 | — | — | US | claimed |
| WO-2004005240-A1 | PROCESS FOR PREPARING NATEGLINIDE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-01-15 | — | — | WO | claimed |
| EP-0814073-B1 | Epimerization of 2- or 4-substituted cyclohexanecarboxylic acids | KATAYAMA SEISAKUSHO (JP) | 2001-09-12 | — | — | EP | claimed |
| US-4786332-A | TOBACCO PRODUCTS | GIVAUDAN CORPORATION (US) | 1988-11-22 | — | — | US | claimed |
| EP-0110362-B1 | FRAGRANCE AND FLAVOUR COMPOSITIONS | L. GIVAUDAN & CIE Société Anonyme (CH) | 1988-04-20 | — | — | EP | claimed |
| US-4606925-A | Flavoring with alkyl-substituted cyclohexyl and cyclohexenyl carboxylic acids | GIVAUDAN CORPORATION (US) | 1986-08-19 | — | — | US | claimed |
| EP-0110362-A2 | Fragrance and flavour compositions | L. GIVAUDAN & CIE Société Anonyme (CH) | 1984-06-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152782-A1 | Process for preparing nateglinide and intermediates thereof | PTMA, DNPEP, TFPI | ROCK2 4085/4885ROCK1 4407/4885LMNA 2945/4885 |
| US-20130165686-A1 | Process for the Preparation of Nateglinide | ANPEP, PREP, PTMA | ROCK2 2974/4885ROCK1 2757/4885LMNA 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.